X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc.

NNASDAQ:XFOR
2.83
USD
-0.29
(-9.29%)
-0.66EPS
292.62MMarket Cap
Mar 23Next Earn
X4 Pharmaceuticals, Inc.
NASDAQ:XFOR
(Nasdaq Stock Market)

Recent

price

2.83

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
4.48
- -
- -
- -
0.38
0.83
0.14
Revenue per Share
-427.92
-742.73
-2,961.5
-2,371.72
-138.94
-92.84
-103.34
-44.33
-17.07
-5.59
-1.87
-0.66
Basic EPS, GAAP
-355.15
-701.9
-2,436.97
-1,661.55
-125.49
-89.92
-83.33
-36.46
-16.29
-20.62
-2.1
-0.66
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-571.02
-941.02
739.26
266.81
240.35
133.94
68.7
18.26
9.16
3.89
2.05
1.38
Book Value per Share
-571.02
-941.02
739.26
266.81
189.93
84.06
50.19
13.98
6.05
-0.91
1.76
1.08
Tangible Book Value per Share
- -
- -
- -
- -
- -
1
1
2
6
7
42
122
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
3
- -
- -
- -
3
35
17
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-1,995.8
- -
- -
- -
-5,529.96
-247.44
-473.95
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
- -
1
1
2
Depreciation Expense
-13
-23
-34
-33
-53
-62
-89
-94
-101
-37
-79
-81
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-2,071.03
- -
- -
- -
-1,464.61
-225.55
-474.74
Profit Margin (%)
2
-6
69
30
120
71
74
106
99
79
236
183
Working Capital
5
10
10
8
22
38
38
36
57
77
76
77
LT Debt
-34
-57
59
22
129
73
64
74
51
22
186
139
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-90.37
-70.81
-61.51
-129.28
-135.58
-161.67
-102.26
-75.99
-80.32
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
- -
- -
LT Borrowings
77
77
77
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
94
96
101
Market Capitalization
390
449
293

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
242
219
198
Cash, Cash Equivalents & STI
234
208
188
Accounts Receivable, Net
1
2
1
Inventories
5
6
6
Total Current Liabilities
24
19
15
Payables & Accruals
19
15
10
ST Debt
1
- -
- -
Deferred Revenue
1
1
1

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
90.93%
131.38%
741.08%
Free Cash Flow
29.09%
11.82%
-35.89%
Net Income, GAAP
30.07%
20.97%
111.48%
Sales/Revenue/Turnover
- -
- -
1,273.21%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
1
1
3
2025
29
2
2
3
35
2026
3
9
3
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-7.77
13.6
-5.48
-5.89
-5.59
2025
0.04
-3.47
-0.69
-0.22
-1.87
2026
-0.16
-0.13
-0.16
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics targeting diseases resulting from dysfunction of the CXCR4 pathway, particularly rare immune disorders with limited treatment options; its lead product, mavorixafor (marketed as XOLREMDI in the U.S.), is an oral, once-daily small-molecule CXCR4 antagonist approved for the treatment of adult patients with WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), a rare primary immunodeficiency, and is under investigation in the ongoing global Phase 3 4WARD trial for chronic neutropenia, including severe congenital neutropenia, idiopathic neutropenia, and neutropenia associated with certain genetic syndromes. Founded in 2014 and headquartered in Boston, Massachusetts, the company operates primarily in the U.S. with ex-U.S. partnerships for mavorixafor commercialization and serves patients with rare diseases of the immune system through its expertise in CXCR4 biology. Recent developments include a $60 million private placement equity financing in August 2025 led by Coastlands Capital with participation from Bain Capital Life Sciences, New Enterprise Associates, and others to support the 4WARD trial and XOLREMDI commercialization, accompanied by management and board changes featuring Dr. Adam Craig as Executive Chairman; a $135 million underwritten public offering priced in late October 2025, which closed at approximately $155 million; strategic restructuring in February 2025 and September 2025 to optimize costs by $30-35 million annually, sharpen focus on chronic neutropenia, and enhance U.S. promotion of XOLREMDI; FDA Fast Track Designation for mavorixafor in chronic neutropenia-related indications; and EMA validation of a Marketing Authorization Application for mavorixafor licensed to Norgine for development outside the U.S.

Company News

  • X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates

  • X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

  • X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026

  • 4 Biotech Stocks Seeing Unusual Options Volume Today

  • X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript

  • X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day

  • X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

  • Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR)

  • X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

  • X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures

  • X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Rated “Moderate Buy” by Sell-Side Brokerages

  • X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround

  • X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $11.25 Consensus Price Target from Brokerages

  • X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

  • X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

  • X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

  • X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

  • X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update